Reuters

Prime Therapeutics’ Clinical Insights is your trusted resource for timely, evidence based perspectives on emerging therapies and managed care strategy. The Summer 2025 issue focuses on metabolic...

A roundup of Prime's award-winning presentations and insights at AMCP Nexus in National Harbor, Maryland

In the U.S. Food and Drug Administration (FDA)’s latest annual report of drug approvals, the agency shared it approved a total of 46 novel drugs in 2025. Here’s how that stacks up against years...

Industry experts share new insights from PBM industry, including GLP-1 weight-loss drugs, biosimilars and rising pharmaceutical costs

A roundup of Prime's award-winning presentations and insights at AMCP 2026 in Nashville, Tennessee

Novartis submitted an application to the FDA in 2Q 2025 for an intrathecal formulation (OAV101IT) of their one-time gene therapy onasemnogene abeparvovec (OAV101IT) for the treatment of spinal...

New indications for approved gene / cell therapy products - 2024 Generic Name Brand Name Manufacturer Indication(s) Route of Administration Month Approved* fidanacogene elaparvovec-dzkt Beqvez™...

Maryam Tabatabai, PharmD, associate vice president of clinical information, shares more about how cell and gene therapies are transforming the treatment landscape, and how payers and providers can...

Hear some of the latest insights from the annual managed care pharmacy event, where Prime Therapeutics clinical and health outcomes teams presented leading research findings